Compare JetBlue Airways Corporation (JBLU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Novartis AG — how do they compare? JetBlue Airways Corporation trades at $3.91 (market cap $1.50B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 182.7× JetBlue Airways Corporation's market cap, and Novartis AG pays a 3.31% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Novartis AG for 82 Days on average.
| JBLU | NVS | |
|---|---|---|
Market Cap | $1.50B | $274.00B |
Volume | 22,018,927 | 1,852,137 |
Sector | Industrials | Health |
52-Week High | $6.46 | $168.62 |
52-Week Low | $3.92 | $121.80 |
Typical Hold Time | 44 Days | 82 Days |
Enterprise Value | $8.86B | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 2.73% on the day, reflecting ongoing challenges. The stock shows a bearish technical trend with key indicators mixed, while fundamentals reveal persistent losses with a negative net income margin of -9.32% and elevated debt levels. Recent news includes route expansion to Colombia but also capacity cuts due to fuel costs, highlighting operational pressures amid a difficult industry environment.
The outlook remains cautious with high debt and consistent earnings misses posing significant risks. However, the consensus price target of $5.89 suggests potential upside if operational improvements materialize. Investors face headwinds from fuel price volatility and competitive pressures, requiring careful monitoring of cost management and travel demand recovery for any sustained rebound.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
